Heparin and pump flow set by lean body mass in obese heart surgery
Tests heparin dosing and pump flow using lean body mass in obese adults.
Plain-language title generated from the registry record
Registry title: Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery
Key facts
- Where
- Québec, CanadaSee the site
Where in Canada
- Hôpital LavalQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Laval University
- Trial code
- NCT03302195
- Record updated
- 10 March 2023
- Original description
Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).Read full original descriptionShow less
Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery
Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).
The purpose of this study is to assess the safety and efficacy of using lean body mass (LBM) to determine pump flow rate and/or Heparin dosage in obese patients undergoing CPB.
Inclusion: Obese patients (BMI ≥ 30kg/m2); Planned cardiac surgery; Age ≥ 18 years.
Exclusion: Patient dosed with low molecular weight Heparin less than 24h before surgery; Dosed with clopidogrel or ticagrelor within the last 5 days prior to surgery, or prasugrel within 7 days; Dosed with GPIIb/IIIa receptor blockers (Abciximab, Tirofiban, Eptifibatide) ≤ 24 hours prior to surgery; Known or suspected allergy to the used antifibrinolytic agent; Known congenital bleeding disorders; Two or more cardiac surgery procedures; Emergency cardiac surgery procedures (medically required within 24hours of presenting with acute symptoms); Any known autoimmune disease; Any history of stroke or non-coronary thrombotic disorders including deep venous thrombosis and pulmonary embolism; Confirmed ST elevation myocardial infarction (STEMI) within 7 days; Current thromboembolic disease other than myocardial infarct; Pre-operative platelet count <100,000/microliter; International ratio (INR) >1.5 on the day of surgery in patients treated with vitamin K antagonist; Liver dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) increased ≥ 2-fold above the upper limit of local laboratory normal ranges); Renal failure (creatinine ≥ 175 micromol/L or dialysis); Permanent pacemaker; Known intolerance to protamine; Refusal to receive blood products; Planned off pump coronary artery bypass; Planned peri-operative use of desmopressin; Known Heparin-induced thrombocytopenia; Known deficiency in protein C, protein S, antithrombin or homozygous factor V Leiden; Current endocarditis; Planned hypothermic circulatory arrest (<28C); Planned CPB priming with red blood cells; Significant (≥50%) carotid artery stenosis; Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods; Anaemia (Hematocrit <32% for females, <35%for males); Patients who have pre-donated autologous blood; Patient presenting with a resistance to Heparin.